Searching…
Nov 17, 2021 · High plasma circulating tumor DNA levels were observed for patients carrying a KRAS A146 mutation versus those with a KRAS G12 mutation, with median mutant allele frequencies of 48% versus 19%, respectively.
KRAS A146T models show a strong sensitivity to Trametinib in vitro treatment, in the absence of additional driver mutations. Heatmap showing the viability of different KRAS mutant PDXs treated for 72 hours with the in...
OncoKB™ is a precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that contains biological and clinical information about genomic alterations in cancer.
All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
NRAS A146T does not lie within any known functional domains of the Nras protein (UniProt.org). A146T has not been characterized, but can be predicted to lead to a gain of Nras protein function and activation of downst...
When bred to a strain expressing Cre recombinase under control of various tissue specific promoters, Cre recombination deletes the LSL cassette and allows the expression of the mutant KRAS oncogenic protein. This stra...
Jun 3, 2019 · We used a cross-disciplinary approach to compare KRAS G12D, a common mutant form, and KRAS A146T, a mutant that occurs only in selected cancers.
Biochemical and structural studies demonstrated that K-Ras A146T exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates K-Ras by promoting a high rate of intrin...
A146T Kras with Flag tag inserted into N-terminal domain between 6Xhis tag and TEV cleavage site.
Jan 23, 2024 · From the pharmacologic point of view, Trametinib monotherapy was more effective in A146T than in G12D -mutated models, suggesting a vulnerability to MEK inhibition.
